AbbVie (NYSE:ABBV – Free Report) had its target price hoisted by Leerink Partners from $309.00 to $342.00 in a research report released on Monday morning,Benzinga reports. They currently have an outperform rating on the stock.
ABBV has been the subject of a number of other research reports. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Morgan Stanley lifted their price target on AbbVie from $310.00 to $346.00 and gave the company an “overweight” rating in a report on Monday. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and upped their price target for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Finally, Canaccord Genuity Group increased their price objective on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $294.67.
View Our Latest Research Report on AbbVie
AbbVie Price Performance
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.86 earnings per share. Analysts anticipate that AbbVie will post 13.92 earnings per share for the current year.
AbbVie Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is 119.10%.
Insider Activity
In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is owned by company insiders.
Institutional Trading of AbbVie
Several hedge funds and other institutional investors have recently modified their holdings of ABBV. Burk Holdings LLC acquired a new stake in shares of AbbVie in the 2nd quarter valued at approximately $30,000. Marquette Asset Management LLC increased its position in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after acquiring an additional 48 shares during the period. Principia Wealth Advisory LLC increased its position in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after acquiring an additional 44 shares during the period. IMG Wealth Management Inc. increased its position in AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after acquiring an additional 153 shares during the period. Finally, Tacita Capital Inc bought a new position in shares of AbbVie during the second quarter valued at $42,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Expanded migraine partnership: AbbVie and Brise Pharmaceuticals announced a global license agreement to advance next-generation migraine treatments, potentially worth up to $757 million. The deal adds another growth opportunity to AbbVie’s neuroscience pipeline. AbbVie, Brise Expand Migraine Drug Partnership
- Positive Sentiment: Positive migraine data: A Phase 3 study published in The Lancet Neurology reportedly delivered a favorable result, supporting the commercial potential of AbbVie’s migraine portfolio. AbbVie Lands Phase 3 Migraine Study Win
- Positive Sentiment: Analyst optimism increased: Cantor Fitzgerald raised its price target to $325, while RBC, Canaccord Genuity, Leerink Partners and Morgan Stanley lifted targets to $330, $338, $342 and $346, respectively. The revisions reflect confidence in AbbVie’s immunology transition and raised outlook. Analysts Increase Forecasts on AbbVie
- Positive Sentiment: Strong operating performance: Third-quarter revenue rose 10.3% to $17.4 billion, while adjusted EPS of $3.82 exceeded expectations. Skyrizi, Rinvoq and neuroscience products are offsetting Humira’s decline, and management raised its 2026 revenue and earnings outlook. ABBV Q3 Earnings Call Highlights
- Positive Sentiment: Dividend increase: AbbVie raised its quarterly dividend 5.2% to $1.82 per share, signaling confidence in cash flow and reinforcing the stock’s income appeal.
- Neutral Sentiment: Legal win: AbbVie prevailed in a lawsuit against the U.S. Department of Health and Human Services concerning drug-price controls, potentially reducing near-term regulatory uncertainty. AbbVie Wins Drug Price Control Lawsuit
- Negative Sentiment: Transition and valuation risks remain: Humira sales continue to decline, leaving investors dependent on Skyrizi, Rinvoq and pipeline launches to sustain growth. After a sharp rally, ABBV’s elevated valuation and proximity to its 52-week high may also be prompting profit-taking despite the positive updates. AbbVie’s Humira Era Is Fading
AbbVie Company Profile
AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.
The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.
Further Reading
- Five stocks we like better than AbbVie
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
